Tolerance to an Artisanal Bread in a Population Intolerant of the Conventional Bread and Study of Associated Markers (TOLERBREAD)
The objective of this study is to evaluate the effect of consuming an "artisanal" bread for 15 days on gastrointestinal symptoms in individuals intolerant to "conventional" bread.
"Conventional bread" refers to bread made with refined wheat flour (ash = 0.55% of dry matter), containing gluten, and leavened with baker's yeast (Saccharomyces cerevisiae). "Artisanal bread" refers to bread made with whole wheat flour (ash = 1.50% of dry matter) from an ancient durum wheat variety (Russello) and leavened with sourdough.
調査の概要
詳細な説明
Abbreviations:
- GSRS-IBS: Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome
- GIQLI: Gastrointestinal Quality of Life Index
- HADS: Hospital Anxiety and Depression Scale
- FSS: Fatigue Severity Scale
- LBP: Lipopolysaccharide-Binding Protein
Inclusion Visit (visit 0 [V0])
At the inclusion visit (V0) at Avicenne Hospital (Bobigny), participants will receive study instructions and materials. They will have up to 15 days to:
- Complete questionnaires (modified GSRS-IBS, Bristol Stool Scale, GIQLI, HADS, FSS)
- Collect a baseline stool sample, stored at -18°C at home until their first hospital visit (V1).
Wash-out phase (Day-15 [D-15] to Day 0 [D0]):
Participants will follow a gluten-free and low-fructan diet for 15 days. During this period:
- Daily food intake will be recorded in a diary, with meal photos sent to the research team via a dedicated email
- On D-8, participants will complete the modified GSRS-IBS and Bristol Stool Scale.
- On D-1, participants will perform a 24-hour urine collection after ingestion of lactulose (10g) and mannitol (10g) in 200 mL water, divided into three containers:
- First morning urine
- 0-5 h collection after sugar ingestion (fasting except water)
- 5-24 h collection Stool will also be collected on D-1 and stored at 4°C until V1.
First investigation day (Day 0 [D0] - V1):
At 9 a.m., participants arrive the Clinical Research Center (at Avicenne Hospital) with their stool and urine samples.
After completing the questionnaires (modified GSRS-IBS, GIQLI, HADS, FSS, and Bristol Stool Scale), a venous catheter will be inserted for blood sampling.
A 10 mL blood sample will be collected before the test meal. Participants will then consume the test meal (105 g of "artisanal" bread with water).
Postprandial blood samples (2 mL each) will be collected every 30 minutes for 3 hours (total blood volume: 22 mL) The modified GSRS-IBS questionnaire will be completed every hour during the postprandial period If a bowel movement occurs during the visit, the stool sample collected at that time may be used to replace the one collected the previous day.
Intervention phase (D1 to D14):
Participants will continue the same gluten-free, low-fructan diet, with the addition of the "artisanal" bread, which will serve as the sole source of gluten source and the main source of fructans.
- D1: 75 g of bread
- D2: 100 g of bread
- D3-14: 125 g of bread daily (≈ 8.5 g gluten, <1.2 g fructans) Bread consumption may be distributed throughout the day. On D8, participants will again complete the modified GSRS-IBS and Bristol Stool Scale.
Second investigation day (D15 - V2):
On D14, participants will repeat the 24-hour urine and stool collection as previously described. On D15, they will return to the research center and undergo the same procedures as V1.
Measurements:
- Questionnaires: modified GSRS-IBS (gastrointestinal symptoms), GIQLI, HADS, FSS.
- Blood: LBP (marker of inflammation), zonulin (marker of intestinal permeability), glucose, insulin.
- Urine: lactulose and mannitol, with calculation of the lactulose/mannitol ratio as a marker of intestinal permeability.
- Stool: microbial community analysis (microbiota) and fecal calprotectin (marker of inflammation). Baseline stool samples (before wash-out phase) will also be used to inoculate an artificial colon model for later investigation of the effects of bread on the microbiota.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Fabien Wuestenberghs
- 電話番号：+330148952276
- メール：fabien.wuestenberghs@aphp.fr
研究連絡先のバックアップ
- 名前：Claire Gaudichon
- 電話番号：+33144081829
- メール：claire.gaudichon@agroapristech.fr
研究場所
-
-
-
Bobigny、フランス、93000
- 募集
- Centre de Recherche sur Volontaires
-
コンタクト：
- Mourad Benallaoua
- メール：mourad.benallaoua@aphp.fr
-
コンタクト：
- Suzette Maurinier
- メール：suzette.maurinier@aphp.fr
-
-
Île-de-France Region
-
Bobigny、Île-de-France Region、フランス、93000
- まだ募集していません
- Centre de Recherche sur Volontaires (CRV)
-
コンタクト：
- Suzette Maurinier
- 電話番号：+331 48 95 74 33
- メール：suzette.maurinier@aphp.fr
-
主任研究者：
- Fabien Wuestenberghs
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Normal weight (18 < BMI < 25 kg.m-2)
- Male or female
- 18 to 65 years old
- Adults reporting intolerance to "conventional" bread
- Absence of celiac disease
- Affiliated to a social security scheme
- Free, informed and express consent
Exclusion Criteria:
- People under protective supervision: legal guardianship, tutorship or curatorship
- People with eating disorders (anorexia, bulimia, binge eating)
- Any known food allergy
- Women who are pregnant or potentially pregnant (based on a positive urine pregnancy test at inclusion)
- Breastfeeding women
- Alcohol abuse (>2 drinks/day). At the time of inclusion, the investigator will assess whether the participant exhibits harmful alcohol consumption
- Untreated hypertension, uncontrolled diabetes, or diseases of the digestive tract (excluding functional intestinal disorders), liver, kidneys, or severe heart disease. The investigator will assess the presence of these conditions on standard clinical criteria and the participants' self-reported medical history at the time of inclusion
- Participation in a clinical study in the three months preceding the study
- Absence of express consent
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Artisanal Bread
"Artisanal" bread is made with wholemeal flour (ash = 1.50% of dry matter) from an ancient durum wheat (Russello variety) and leavened with sourdough. "Artisanal" bread contains 6.8g of gluten and less than 1g of frutans per 100g. |
During the second part of the study (from Day 1 [D1] to Day 14 [D14]), participants will consume the "artisanal" bread on a daily basis. Dose: D1 = 75g; D2 = 100g; from D3 to D14: 125g/day On D0 and D15, volunteers will come to the hospital for 3 hours of postprandial testing. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intensity of gastrointestinal symptoms
時間枠：Scores at Day 0 [D0] and Day 15 [D15]
|
The severity of gastrointestinal symptoms will be assessed using a score from the modified GSRS-IBS questionnaire used in this study. This score consists of 13 questions ranging from 1 (Not at all) to 7 (Very severely) on a Likert scale. Thus, the total score can range from 13 to 91, with higher scores indicating more severe gastrointestinal symptoms and, consequently, lower tolerance. The scores obtained before and after the diet including the "artisanal" bread will be compared. |
Scores at Day 0 [D0] and Day 15 [D15]
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intensity of gastrointestinal and extraintestinal symptoms
時間枠：Scores at Day 0 [D0] and Day 15 [D15]
|
The intensity of gastrointestinal and extra-intestinal symptoms will be assessed using the total score of the modified version of the GSRS-IBS questionnaire. Scores obtained before and after the diet including the "artisanal" bread will be compared. The score is measured on a 7-point Likert scale, ranging from 1 (Not at all) to 7 (Very severely). The questionnaire consists of 28 questions, so total scores can range from 28 to 196, with higher scores indicating more severe gastrointestinal and extra-intestinal symptoms and, therefore, lower tolerance. |
Scores at Day 0 [D0] and Day 15 [D15]
|
|
Validity of the modified GSRS-IBS
時間枠：Scores of the two questionnaires at Day [D0] and Day [D15]
|
Correlations between the scores from the GSRS-IBS and the modified GSRS-IBS used in this study will be analyzed. The GSRS-IBS score can be obtained from the modified GSRS-IBS questionnaire. This questionnaire consists of 7-point Likert scale ranging from 1 (No discomfort at all) to 7 (Very severe discomfort) for 13 items. The total score therefore ranges from 13 to 91. An increase in this score indicates greater gastrointestinal discomfort and, consequently, lower tolerance. The modified GSRS-IBS questionnaire comprises 28 items scored on a 7-point Likert scale, ranging from 1 (Not at all) to 7 (Very severely). Thus, the total score of this questionnaire ranges from 28 to 196. An increase in this score indicates greater gastrointestinal symptoms and, consequently, lower tolerance. These two scores will be compared, and their correlation analyzed. |
Scores of the two questionnaires at Day [D0] and Day [D15]
|
|
Comparison between volunteers' perceived tolerance of "artisanal" bread and measured tolerance
時間枠：Scores at Day 0 [D0] and Day 15 [D15]
|
In addition to the intensity scores calculated for each symptom (the sum of which constitutes an objective total score), participants will give a global subjective assessment of their tolerance to the "artisanal" bread using a scale from 0 (absence of symptoms) to 10 (extremely intense symptoms).
The objective and subjective scores will then be compared, and their correlation analyzed.
|
Scores at Day 0 [D0] and Day 15 [D15]
|
|
Clinical profile of response to the "artisanal" bread
時間枠：These scores are measured at Day 0 [D0], Day 8 [D8] and Day 15 [D15].
|
Individual symptoms will be grouped into symptom groups (pain, reflux, indigestion, diarrhea and constipation).
A score will be calculated for each groupe, and these scores will be compared.
|
These scores are measured at Day 0 [D0], Day 8 [D8] and Day 15 [D15].
|
|
Evaluation of intestinal permeability
時間枠：Measured on Day D0 [D0] and Day 15 [D15]
|
Intestinal permeability will be assessed by measuring serum zonulin levels and the urinary lactulose/mannitol ratio.
|
Measured on Day D0 [D0] and Day 15 [D15]
|
|
Evaluation of intestinal inflammation
時間枠：Serum LBP : measured on Day 0 [D0] and Day D15 [D15] Fecal calprotectin : measured in stool samples collected at Day-1 [D-1] and Day 14 [D14].
|
Intestinal inflammation will be assessed by measuring serum LBP and faecal calprotectin.
|
Serum LBP : measured on Day 0 [D0] and Day D15 [D15] Fecal calprotectin : measured in stool samples collected at Day-1 [D-1] and Day 14 [D14].
|
|
Microbiota composition
時間枠：Determined in stool samples collected at visit 0 [V0], on Day -1 [D-1] and Day 14 [D14]
|
The relative abundance of bacterial genera in stool samples at the end of each diet (with and without bread) will be compared. Stool samples will also be collected at inclusion (visit 0 [V0]) to determine the baseline microbiota and to inoculate an in vitro artificial colon model. |
Determined in stool samples collected at visit 0 [V0], on Day -1 [D-1] and Day 14 [D14]
|
|
Tolerance profiles for "artisanal" bread
時間枠：From the enrollment (visit 0 [V0]) to the end of the study (Day 15 [D15])
|
Exploration of tolerance profiles to "artisanal" bread without a priori, and their characterization based on clinical data (questionnaires) and biological markers (inflammation, intestinal permeability, and microbiota).
|
From the enrollment (visit 0 [V0]) to the end of the study (Day 15 [D15])
|
|
Postprandial glucose responses measured after consumption of the test meal ("artisanal bread")
時間枠：Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
Blood glucose levels measured every 30 minutes for 3 hours after the test meal
|
Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
|
Postprandial insulin responses measured after consumption of the test meal ("artisanal bread")
時間枠：Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
Blood insulin levels measured every 30 minutes for 3 hours after the test meal
|
Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
|
Substrate oxidation rates
時間枠：Measured at 0; 0.5; 1.5 and 2.5 hours after test meal
|
Fat and glucose oxidation assessed by measuring respiratory exchanges using indirect calorimetry
|
Measured at 0; 0.5; 1.5 and 2.5 hours after test meal
|
|
H2 concentrations in exhaled air
時間枠：Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
H2 concentration in air measured every 30 minutes for 3 hours after test meal
|
Measured at 0; 0.5; 1; 1.5; 2; 2.5 and 3 hours after test meal
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- TOLERBREAD
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。